MetaCap

Abbott Laboratories (ABT) vs Pfizer (PFE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pfizer (PFE) has outperformed Abbott Laboratories (ABT) over the past year, gaining 9.4% versus a loss of 19.6%. Over five years, ABT leads with a -18.2% price change compared with -49.3% for PFE. Abbott Laboratories is the larger company by market cap ($178.39 billion vs $156.18 billion), about 1.1 times the size.

On valuation, Pfizer trades at a lower forward P/E (9.3x vs 17.3x for Abbott Laboratories). Pfizer offers the higher dividend yield (7.85% vs 2.45%). Abbott Laboratories converts more of its revenue into profit, with a net margin of 14.7% versus 12.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABT-19.60%PFE+9.42%
+26%-6%-38%
Nov 21, 20251 yearNov 20, 2026
ABT-18.80%PFE-46.06%
+21%-20%-61%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABT versus PFE key metrics
MetricABTPFE
Share price$103.00$27.40
Market cap$178.39B$156.18B
1-day change-0.84%-0.51%
YTD return-17.79%+10.04%
1-year return-19.60%+9.42%
5-year return-18.18%-49.26%
P/E ratio (TTM)38.4339.14
Forward P/E17.359.28
EPS (TTM)$2.68$0.70
Dividend yield2.45%7.85%
Annual dividend$2.52$2.15
Revenue (latest FY)$44.33B$62.58B
Revenue growth (YoY)+5.67%-1.65%
Net income (latest FY)$6.52B$7.77B
Gross margin56.42%74.33%
Operating margin18.17%—
Net margin14.72%12.42%
52-week high$129.85$31.44
52-week low$81.97$23.62
Distance from 52-week high-20.68%-12.85%
Analyst consensusbuybuy
Avg. price target upside+15.45%+10.29%
Average volume8.89M33.52M
Shares outstanding1.73B5.70B
Employees122,00075,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PFE has outperformed ABT by 29.0 percentage points over the past year.
  • Pfizer offers a meaningfully higher dividend yield (7.85% vs 2.45%).
  • Abbott Laboratories grew revenue faster in its latest fiscal year (+5.67% vs -1.65%).

About Abbott Laboratories

ABT stock →

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Health Care · Biotechnology: Pharmaceutical Preparations · 122,000 employees

About Pfizer

PFE stock →

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees

ABT vs PFE FAQ

Which is bigger, Abbott Laboratories or Pfizer?

Abbott Laboratories (ABT) is larger, with a market capitalization of $178.39B compared with $156.18B for Pfizer (PFE).

Which stock has performed better over the past year, ABT or PFE?

PFE returned +9.42% over the past 12 months, compared with -19.60% for ABT (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ABT or PFE?

ABT has the lower trailing P/E at 38.4, versus 39.1 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Abbott Laboratories or Pfizer?

Pfizer has the higher yield at 7.85%, compared with 2.45% for Abbott Laboratories.

Are Abbott Laboratories and Pfizer in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons